Roquefort Therapeutics (LON:COIL) Releases Quarterly Earnings Results

Roquefort Therapeutics (LON:COIL) issued its quarterly earnings data on Wednesday. The company reported GBX (2.19) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 18.30%.

Roquefort Therapeutics Stock Performance

Shares of COIL stock traded up GBX 0.50 on Wednesday, hitting GBX 8. The company had a trading volume of 2,363 shares, compared to its average volume of 154,688. The firm has a market cap of £34.07 million, a P/E ratio of -1.27 and a beta of 0.05. The company has a 50-day moving average price of GBX 9.17 and a 200-day moving average price of GBX 12.82. The company has a quick ratio of 3.07, a current ratio of 2.80 and a debt-to-equity ratio of 8.07. Roquefort Therapeutics has a twelve month low of GBX 6.75 and a twelve month high of GBX 10.

About Roquefort Therapeutics

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.